Results · Apr-Jun 2026
Lincoln Pharmaceuticals Q1 FY27 results
Very strongVery strong: sales up 15% or more & profit up 25% or more on the same quarter last year, with a wider operating margin.
Sales grew 15% to ₹177 crore from ₹154 crore in Apr-Jun 2025.
Operating profit grew 15% to ₹27.4 crore, an operating margin of 15.5% (unchanged from a year ago).
Net profit grew 31% to ₹36.2 crore from ₹27.7 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −5%, net profit +211%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 177.3 | 154.1 | +15% |
| Operating profit (EBITDA) | 27.4 | 23.8 | +15% |
| Operating margin | 15.5% | 15.5% | 0.0 pts |
| Net profit | 36.2 | 27.7 | +31% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.